PTAB Ruling Used New Arguments, Genzyme Tells Fed. Circ.
Genzyme Therapeutic Products urged a Federal Circuit panel Thursday to reverse a Patent Trial and Appeal Board decision gutting its two patents covering methods of treating a muscle disease, insisting the...To view the full article, register now.
Already a subscriber? Click here to view full article